Claris Lifesciences Ltd forays into stringent EU market

New Delhi, Jun 19 (UNI) Claris Lifesciences Ltd today said it had initiated the first supply of its complex Lipid Emulsion to Delta Select -- a subsidiary of Plasma Select, Germany, one of the leading hospital supply companies in the country.

With this supply, Claris has crossed the milestone of its successfully implementing its regulated markets strategy and gaining access to the highly stringent EU market, thus joining the ranks of a few companies in the world to supply such complex products to the EU.

The company's manufacturing facility based at Ahmedabad, which manufactures this product, has been approved by key international Regulatory Authorities including MHRA (UK), TGA (Australia), NAM (Finland), GCC (Gulf) and Envisa (Brazil).

The regulated markets including Europe, US, Australia and New Zealand are a major focus area for Claris in its strategy for business growth.

The European and US markets together are estimated to be around 120 billion dollars, of which the German market is around 10 billion dollars.

Claris already has 6 ANDAs filed in the US and over 40 Marketing Authorisation Applications registered in the EU, which will significantly enhance its presence in the region by 2006-07.

Claris Lifesciences is an international pharmaceutical company, in the business of manufacturing and marketing sterile parenteral preparations, life saving medicines and hospital products, and focuses on delivery systems, for treatment of critical illness and disease.

Though the company enjoys market leadership in India, it operates in more than 60 countries.

UNI RA ARB PC2053